Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG-3246 in Metastatic Castration-Resistant Prostate Cancer
NCT06842498Phase 2Recruiting
- Sponsor
- Kyntra Bio
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Kyntra Bio. Started Feb 2026; status: recruiting.
02
Drugs
FG-3246
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06842498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842498.